A Surge in Cell and Gene Therapy Market
The global market for cell and gene therapy (CGT) is witnessing an unprecedented surge, projected to grow from
$14.1 billion in 2024 to well over
$28 billion by 2030. This report, released by
Kalorama Information, a prominent authority in healthcare market research, sheds light on the factors catalyzing this growth, including scientific breakthroughs, market expansion, and approvals of next-generation products.
Dominating the Market
Currently,
Novartis is at the forefront of the CGT industry, primarily due to its innovative
Kymriah therapy for oncology, along with gene therapy for muscular atrophy called
Zolgensma. Following closely is
Gilead Sciences, which has made significant strides with its
Yescarta and
Tecartus therapies tailored for oncology.
Novartis holds a notable
17% market share, while Kite (a division of Gilead) comes in at 14%, showcasing a concentrated competitive landscape as oncology therapies command revenue, particularly in North America. However, in Europe, the growth is notable in neurology, indicating shifting regional market dynamics.
Emerging Therapeutic Areas
While oncology remains the leading area, new and promising developments in therapeutic fields such as musculoskeletal, dermatology, and cardiovascular medicine are beginning to emerge. This diversification is essential as the CGT market matures, addressing a broader range of healthcare needs.
Market Dynamics and Challenges
One crucial trend highlighted in the report is the
15%+ compound annual growth rate (CAGR) in oncology, particularly supported by advancements in
CAR T-cell therapies and lymphoma treatments. The CGT industry is also seeing significant momentum with RNA and antisense therapy adoption, although there is ongoing regulatory ambiguity, especially regarding mRNA's classification in various regions.
Additionally, the report emphasizes an impending transformation in the industry regarding the
industrialization and standardization of manufacturing processes. To maintain competitive edge, companies are adopting increased automation and closed manufacturing systems to ensure quality and efficiency. Business leaders are also experimenting with innovative models focused on cost reduction, accessibility, and scalability of CGT solutions.
Importance of the Report
This comprehensive market analysis features over
100 tables and charts, providing essential insights and strategic guidance for professionals involved in:
- - Research and Development (R&D), targeting emerging competitive opportunities.
- - Corporate development leaders, looking for merger and acquisition (M&A) opportunities and early-stage investments.
- - Marketing and regulatory professionals planning for product launches and global expansion.
In the ever-competitive landscape of biopharma and biotech, understanding these dynamics is crucial for success. This report is a must-read for executives engaged in biopharma, biotech startups, Contract Development and Manufacturing Organizations (CDMOs), life sciences investment, and healthcare strategies.
In conclusion, with the cell and gene therapy market set for remarkable growth, stakeholders are prompted to leverage these insights to harness new possibilities within this evolving industry.